A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Public ClinicalTrials.gov record NCT06941272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of HER3-DXd in children and if they tolerate it * What happens to HER3-DXd in children's bodies over time * If children who receive HER3-DXd have the cancer get smaller or go away
Study identification
- NCT ID
- NCT06941272
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 1 Month to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 25, 2025
- Primary completion
- Dec 29, 2030
- Completion
- Dec 29, 2030
- Last update posted
- Aug 27, 2026
2025 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles ( Site 3006) | Los Angeles | California | 90027 | Recruiting |
| Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016) | Aurora | Colorado | 80045 | Recruiting |
| Johns Hopkins All Children's Hospital ( Site 3025) | St. Petersburg | Florida | 33701 | Recruiting |
| University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017) | Iowa City | Iowa | 52242 | Recruiting |
| Dana-Farber Cancer Institute ( Site 3013) | Boston | Massachusetts | 02215 | Recruiting |
| Corewell Health ( Site 3001) | Grand Rapids | Michigan | 49503 | Recruiting |
| Children's Mercy Hospital ( Site 3024) | Kansas City | Missouri | 64108 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 3008) | New Brunswick | New Jersey | 08901 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 3010) | New York | New York | 10065 | Recruiting |
| New York Medical College ( Site 3023) | Valhalla | New York | 10595 | Recruiting |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3003) | Fargo | North Dakota | 58102 | Recruiting |
| Oregon Health and Science University ( Site 3004) | Portland | Oregon | 97239 | Recruiting |
| Children's Hospital of Philadelphia (CHOP) ( Site 3021) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Sanford Children's Hospital ( Site 3015) | Sioux Falls | South Dakota | 57117 | Recruiting |
| University of Texas-MD Anderson Cancer Center ( Site 3007) | Houston | Texas | 77030 | Recruiting |
| Intermountain - Primary Children's Hospital ( Site 3014) | Salt Lake City | Utah | 84113 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06941272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06941272 live on ClinicalTrials.gov.